Digital Content 
NEWS #PharmaBuzz
25 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/mazdutide-9mg-supplementary-application-accepted-for-review-by-chinas-nmpa-potentially-offering-a-novel-drug-option-for-moderate-to-severe-obese-population-302625421.html
20 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/mazdutide-9-mg-achieves-up-to-20-1-weight-loss-in-chinese-adults-with-obesity-glory-2-study-meets-primary-and-all-key-secondary-endpoints-302620471.html
27 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovents-mazdutide-shows-superiority-in-glycemic-control-with-weight-loss-over-semaglutide-in-a-head-to-head-phase-3-clinical-trial-dreams-3-302594633.html
19 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-received-approval-from-chinas-nmpa-for-glycemic-control-in-adults-with-type-2-diabetes-302561434.html
28 Jun 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/china-approval-lilly-and-innovents-mazdutide-breaks-new-class-glp-1-obesity-drugs
15 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-announces-completion-of-first-participant-dosed-in-the-seventh-phase-3-clinical-trial-glory-osa-of-mazdutide-in-china-302481798.html
Share 